SynthesisDrug design, development and therapy2017
Vitamin D levels in systemic sclerosis patients: a meta-analysis.
Synthesis in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis.Nutrients · 2023Pooled it
- Dualities of the vitamin D in systemic sclerosis: a systematic literature review.Advances in rheumatology (London, England) · 2021Pooled it
- Role of Vitamin D in Systemic Sclerosis: A Systematic Literature Review.Journal of immunology research · 2021Pooled it
- A meta-analysis of fracture risk and bone mineral density in patients with systemic sclerosis.Clinical rheumatology · 2020Pooled it
- Does Vitamin D Deficiency Affect the Immunogenic Responses to Influenza Vaccination? A Systematic Review and Meta-Analysis.Nutrients · 2018Pooled it
- Vitamin D and Its Role in Rheumatic Diseases.Metabolites · 2025Review
- Vitamin D Status in Patients with Primary Antiphospholipid Syndrome (PAPS): A Systematic Review and Meta-Analysis.Antibodies (Basel, Switzerland) · 2024Review
- Can vitamin D be an adjuvant therapy for juvenile rheumatic diseases?Rheumatology international · 2023Review
- Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19.Nature reviews. Rheumatology · 2023Review
- Vitamin D and Autoimmune Rheumatic Diseases.Biomolecules · 2023Review
- Fly Me to the Immune: Immunonutrition in Rheumatic Diseases.Mediterranean journal of rheumatology · 2023Article
- Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) with postural orthostatic tachycardia syndrome after silicone breast implantation: Case report.European journal of rheumatology · 2023Article
- Vitamin D status in ANCA-associated vasculitis.Rheumatology advances in practice · 2023Article
- An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases.International journal of molecular sciences · 2022Review
- Review
- The Immunomodulatory Properties of Vitamin D.Mediterranean journal of rheumatology · 2022Review
- The Immunologic Profile of Vitamin D and Its Role in Different Immune-Mediated Diseases: An Expert Opinion.Nutrients · 2022Review
- Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- Micronutrient Deficiencies in Systemic Sclerosis: A Scoping Review.Open access rheumatology : research and reviews · 2022Article
- Diet in Scleroderma: Is There a Need for Intervention?Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate the association between vitamin D and systemic sclerosis (SSc) by meta-analysis.
methodsA comprehensive search was performed through June 12, 2017. Pooled standardized mean difference (SMD) was used to estimate the mean vitamin D difference between case and control groups (or between diffused- and limited-type SSc). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were used to assess the impact of vitamin D level on clinical characteristics of SSc patients. All statistical analyses were performed using Revman 5.0 software.
resultsThe search yielded six studies with a total of 554 SSc patients and 321 healthy controls. The meta-analysis showed that SSc patients suffered from decreased vitamin D levels (SMD =-8.72 ng/mL; 95% CI: -10.11 to -7.32) compared with healthy controls. The meta-analysis results of three studies with 240 SSc patients (93 diffused-type and 147 limited-type SSc patients) showed that diffused-type SSc patients exhibited lower vitamin D levels (SMD =-4.71 ng/mL; 95% CI: -8.98 to -0.44) compared with limited-type SSc patients. However, vitamin D level was not found to be associated with Rodnan score (SMD =-2.29 ng/mL, 95% CI: -8.49 to 3.91,
conclusionSSc patients exhibited lower vitamin D levels compared with healthy controls. Vitamin D levels in diffused-type SSc patients were significantly lower than those in limited-type SSc patients. The severity of clinical features was not associated with the extent of vitamin D deficit. Therefore, we hypothesize that SSc patients, especially diffused type, have lower vitamin D levels, and that the decrease of vitamin D levels might not be an accelerating factor of SSc severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.